We are live on ! Find out more
NVS icon

Novartis

1,383 hedge funds and large institutions have $16.2B invested in Novartis in 2025 Q2 according to their latest regulatory filings, with 119 funds opening new positions, 494 increasing their positions, 476 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 75

21% more funds holding in top 10

Funds holding in top 10: 1417 (+3)

5% more capital invested

Capital invested by funds: $15.4B → $16.2B (+$811M)

2% more funds holding

Funds holding: 1,3561,383 (+27)

4% more repeat investments, than reductions

Existing positions increased: 494 | Existing positions reduced: 476

0.27% less ownership

Funds ownership: 6.59%6.32% (-0.27%)

19% less call options, than puts

Call options by funds: $269M | Put options by funds: $331M

Holders
1,383
Holders Change
+27
Holders Change %
+1.99%
% of All Funds
18.21%
Holding in Top 10
17
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+21.43%
% of All Funds
0.22%
New
119
Increased
494
Reduced
476
Closed
75
Calls
$269M
Puts
$331M
Net Calls
-$61.7M
Net Calls Change
-$26.9M

NVS Hedge Fund Activity: Q2 2025 in Review

1,383 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2025, worth a combined $16.2B — up 5.3% from $15.4B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new NVS positions and 75 closed out — a net gain of 44 holders — while 494 added to existing stakes and 476 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $56.8M. The largest seller was CIBC World Market, cutting an estimated $192M.

  • 1,383 institutional investors held Novartis (NVS) as of Q2 2025, up from 1,356 in Q1 2025.
  • Funds reported $16.2B of Novartis stock for Q2 2025, up 5.3% quarter-over-quarter.
  • 119 funds opened new Novartis positions in Q2 2025 and 75 closed out, a net change of +44 holders.
  • The largest Novartis buyer in Q2 2025 was Morgan Stanley, an estimated $56.8M added.
  • The largest Novartis seller in Q2 2025 was CIBC World Market, an estimated $192M sold.

Based on aggregated 13F filings for Q2 2025.